Peripheral Neuropathy Treatment Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-04-15　·　168 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 2,071.9 Mn
2033 年預估規模: USD 2,564.7 Mn
年複合成長率 CAGR: 3.1%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-04-15頁數 168報告編號 CMI4363

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Peripheral Neuropathy Treatment Market, By Indication (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, and Others), By Treatment (Pharmacological Therapies and Non-pharmacological Therapies), By End User (Hospitals, Ambulatory Centers, and Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

報告摘要

The global peripheral neuropathy treatment market is estimated to be valued at USD 2,071.9 Mn in 2026 and is expected to reach USD 2,564.7 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 3.1% from 2026 to 2033. Global peripheral neuropathy treatment market represents an important part of the neurological treatments market which includes treatment of a common ailment that develops due to impairment of the peripheral nervous system. The condition is characterized by symptoms like pain, numbness, tingling, and muscle weakness which have a huge effect on the quality of patients' lives. The condition results from different causes such as diabetes mellitus, neurotoxicity, resulting from chemotherapy, auto-immune responses, infection, and genetics, among others The market is experiencing substantial growth owing to increasing prevalence of diabetes around the globe, increased geriatric population, and high awareness of neuropathy diseases. These factors mean that there is increased number of patients requiring treatment for the condition. Healthcare organizations, as well as manufacturers of medications used to treat peripheral neuropathy, are investing in development of new therapies which not only manage the symptoms, but also help reverse some aspects of the disease. Market Dynamics The global peripheral neuropathy treatment market is mainly fueled by the increase in the incidence of Diabetes Mellitus, which is the most common cause of neuropathy and results in almost 50% of people with diabetes experiencing nerve damage, thus forming a large patient population that needs constant therapy. Moreover, the rise in cancer cases has led to an explosion in CIPN cases, owing to the higher survival rate resulting in an increased emphasis on coping with adverse effects of treatment. The increase in the geriatric population base acts as another important driver of the market's growth. Nevertheless, there exist some difficulties associated with the heterogeneity of peripheral neuropathy. It makes diagnosing the condition and treating it rather problematic. Besides, the regulatory process for innovative drugs, especially pain killers, and the expensive nature of high-quality treatments reduce their availability on a wider scale, specifically in developing countries. Moreover, the lack of reliable biomarkers reduces the speed of developing and testing new medications. Nonetheless, prospects can be found in the creation of disease-modifying agents and digital health technologies, including remote patient monitoring and telemedicine. Key Features of the Study • This report provides in-depth analysis of the global peripheral neuropathy treatment market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global peripheral neuropathy treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Pfizer Inc., Eli Lilly and Company, Novartis AG, Johnson & Johnson, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Abbott Laboratories, AstraZeneca PLC, Sanofi, and Merck & Co., Inc. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global peripheral neuropathy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global peripheral neuropathy treatment market Market Segmentation • Indication Insights (Revenue, USD Mn, 2021 - 2033) o Diabetic Peripheral Neuropathy o Chemotherapy-induced Peripheral Neuropathy o Idiopathic Peripheral Neuropathy o Others • Treatment Insights (Revenue, USD Mn, 2021 - 2033) o Pharmacological Therapies o Non-pharmacological Therapies • End User Insights (Revenue, USD Mn, 2021 - 2033) o Hospitals o Ambulatory Centers o Others • Regional Insights (Revenue, USD Mn, 2021 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Pfizer Inc. o Eli Lilly and Company o Novartis AG o Johnson & Johnson o GlaxoSmithKline plc o Teva Pharmaceutical Industries Ltd. o Abbott Laboratories o AstraZeneca PLC o Sanofi o Merck & Co., Inc.

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Global Peripheral Neuropathy Treatment Market, By Indication  Global Peripheral Neuropathy Treatment Market, By Treatment  Global Peripheral Neuropathy Treatment Market, By End User  Global Peripheral Neuropathy Treatment Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Regulatory Scenario o Key Developments o Industry Trends 4. Global Peripheral Neuropathy Treatment Market, By Indication, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Diabetic Peripheral Neuropathy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Chemotherapy-induced Peripheral Neuropathy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Idiopathic Peripheral Neuropathy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 5. Global Peripheral Neuropathy Treatment Market, By Treatment, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Pharmacological Therapies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Non-pharmacological Therapies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 6. Global Peripheral Neuropathy Treatment Market, By End User, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Hospitals  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Ambulatory Centers  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 7. Global Peripheral Neuropathy Treatment Market, By Region, 2021 - 2033, Value (USD Mn) o Introduction  Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)  Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn) o South Africa o North Africa o Central Africa 8. Competitive Landscape o Pfizer Inc.  Company Highlights  Product Portfolio  Key Developments  Financial PerTreatmentance  Strategies o Eli Lilly and Company  Company Highlights  Product Portfolio  Key Developments  Financial PerTreatmentance  Strategies o Novartis AG  Company Highlights  Product Portfolio  Key Developments  Financial PerTreatmentance  Strategies o Johnson & Johnson  Company Highlights  Product Portfolio  Key Developments  Financial PerTreatmentance  Strategies o GlaxoSmithKline plc  Company Highlights  Product Portfolio  Key Developments  Financial PerTreatmentance  Strategies o Teva Pharmaceutical Industries Ltd.  Company Highlights  Product Portfolio  Key Developments  Financial PerTreatmentance  Strategies o Abbott Laboratories  Company Highlights  Product Portfolio  Key Developments  Financial PerTreatmentance  Strategies o AstraZeneca PLC  Company Highlights  Product Portfolio  Key Developments  Financial PerTreatmentance  Strategies o Sanofi  Company Highlights  Product Portfolio  Key Developments  Financial PerTreatmentance  Strategies o Merck & Co., Inc.  Company Highlights  Product Portfolio  Key Developments  Financial PerTreatmentance  Strategies 9. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 10. References and Research Methodology o References o Research Methodology o About us *Browse 32 market data tables and 28 figures on ‘Peripheral Neuropathy Treatment Market' - Global forecast to 2033

提及公司

Pfizer Inc.Eli Lilly and CompanyNovartis AGJohnson & JohnsonGlaxoSmithKline plcTeva Pharmaceutical Industries Ltd.Abbott LaboratoriesAstraZeneca PLCSanofiMerck & Co., Inc.

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們